Misplaced Pages

AZD2693

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)
Pharmaceutical compound
AZD2693
Clinical data
Other namesION839
Legal status
Legal status
  • Investigational
Identifiers
CAS Number

AZD2693 is an antisense therapy developed by AstraZeneca for the treatment of non-alcoholic fatty liver disease based on the PNPLA3 gene, believed to be the largest single genetic risk factor for this condition.

References

  1. Dolgin, Elie (1 May 2023). "NASH therapies head toward landmark approval". Nature Biotechnology. 41 (5): 587–590. doi:10.1038/s41587-023-01787-8. ISSN 1546-1696. PMID 37142707.
  2. Cherubini, Alessandro; Casirati, Elia; Tomasi, Melissa; Valenti, Luca (2 December 2021). "PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date". Expert Opinion on Therapeutic Targets. 25 (12): 1033–1043. doi:10.1080/14728222.2021.2018418. hdl:2434/889573. PMID 34904923.
  3. Sasso, Janet M.; Ambrose, Barbara J. B.; Tenchov, Rumiana; Datta, Ruchira S.; Basel, Matthew T.; DeLong, Robert K.; Zhou, Qiongqiong Angela (26 May 2022). "The Progress and Promise of RNA Medicine─An Arsenal of Targeted Treatments". Journal of Medicinal Chemistry. 65 (10): 6975–7015. doi:10.1021/acs.jmedchem.2c00024. PMC 9115888. PMID 35533054.
  4. Pirola, Carlos J.; Sookoian, Silvia (November 2021). "PNPLA3 and COVID-19 outcomes: Thinking outside the box might explain the biology behind pleiotropic effects of rs738409 on the immune system". Liver International. 41 (11): 2801–2804. doi:10.1111/liv.15043. ISSN 1478-3223. PMC 8662082. PMID 34455682.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: